Antibody avidity fulfills various myeloma In the continuing look for impressive treatments to overcome refractory and relapsed cancer, new preclinical operate in various myeloma displays that expanding binding avidity by targeting two antigens in one T mobile-partaking trispecific antibody boosts anti-tumor activity and cuts down the chance of tumo